lanreotide

Overview

Lanreotide is a synthetic somatostatin analog (long-acting depot formulation) targeting SSTR2 and SSTR5, used for antiproliferative and antisecretory therapy in neuroendocrine tumors. It is approved for unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic NETs.

Evidence in the corpus

• High SSTR2 expression identified by WGTA (POG program) supported somatostatin-analog therapy (octreotide/lanreotide) in metastatic NEN patients PN5, PN7, PN10, PN23, PN28; PN23 had a 1972-day duration on octreotide/lanreotide PMID:24326773

Resistance mechanisms

Cancer types (linked)

• PANET
• LNET

Sources

This page was processed by crosslinker on 2026-05-09.